Close Up International – Norberto Bonaparte, Founder and CEO –…
The founder and president of Close Up International shares the story of the genesis, evolution, and growth of both his company and the prescription auditing industry, as well as his…
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. At present, Aegerion is in the process of registering lomitapide in markets worldwide, and plans to conduct clinical development activities to support a marketing authorization application for lomitapide in HoFH in Japan and in support of our planned clinical study of lomitapide in pediatric and adolescent HoFH patients.
Contact info:
Rosario Cestau
Country Manager, Argentina
Av. Libertador 2442, Suite 406 {B1636DSR} Olivos, Buenos Aires
Tel: +5411 – 4711 8228 | Mobile: +54 911 3874 7608
rcestau@aegerion.com | www.aegerion.com
The founder and president of Close Up International shares the story of the genesis, evolution, and growth of both his company and the prescription auditing industry, as well as his…
The executive director of Latin America’s largest plasma fractionation plant, a publicly-funded laboratory within the 400 year old National University of Cordoba, discusses the organization’s social responsibility as a provider and leader…
Over the course of a day of unprecedented collaboration, Argentina’s biotech industry came together to discuss the challenges facing their industry in Argentina and the region at BioArgentina 2014, an event…
Nicola Carusoni, PwC’s lead pharmaceutical partner in Buenos Aires, gives an overview of the key trends in the Argentinian pharma industry and discusses the importance of PwC as a partner to the…
Mauro Bono discusses the challenges of building a company from the interior of Argentina, and shares his assessment of the key issues driving and preventing change in the country’s pharmaceutical…
Glenmark’s country manager for Argentina discusses Argentina’s development expertise and how companies like Glenmark can capitalize on it through partnerships and collaborations. How did you become part of Glenmark,…
“We are glad to host, together with ETIF, an event bringing forward pharma technologies to Argentinian patients. We hope this collaboration with ETIF will be the first of many” – Ines…
President of the company, Alberto Alvarez-Saavedra, discusses the company’s transformation into a professional organization, and the strategy which has driven remarkable growth in recent years, and will continue to do so…
On behalf of the chamber of industry that represents research-based pharma and biopharma companies in Argentina, Ernesto Felicio discusses the current challenges facing the industry, and the chambers current agenda…
Long-term strategy is the name of the game for Janssen. Alejandro Smolje, the company’s director of finance for Latin America South, outlines how that strategy is implemented in Argentina and…
Gabriela Pittis discusses the Argentinian healthcare system’s ability to diagnose, treat, and regulate rare diseases, and the country’s progress in further developing what is already the region’s most comprehensive system…
The director general of the Argentina, Uruguay and Paraguay region for Sanofi discusses the strength of the Argentinian healthcare system and the key, but subdued, role that multinational pharmaceutical companies…
See our Cookie Privacy Policy Here
